



PATENTS

#2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

O'Reilly et al.

Serial No. 10/042,347

Filed: January 11, 2002

For: Nucleic Acid Molecules Encoding
Endostatin Protein and Peptide
Fragments Thereof

)

)

)

) Art Unit: 1642

)

) Examiner: Sheela J. Huff

)

)

)

)

)

RECEIVED

AUG 15 2002

TECH CENTER 1600/2000


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTAssistant Commissioner for Patents
Washington, DC 20231

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

This Supplemental Information Disclosure Statement is being filed before the mailing of the first Office Action on the merits (37 C.F.R. 1.97(b)(3)); therefore, no fee is believed to be required. However, if a first Office Action on the merits has issued, please consider this Information Disclosure Statement under 37 C.F.R. 1.97(c). The Commissioner is hereby authorized to charge the applicable fees, if any, to Deposit Account No. 11-0855.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on August 08, 2002


Jamie L. Greene - Reg. No. 32,467



The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Jamie L. Greene
Reg. No. 32,467


KILPATRICK STOCKTON LLP
1100 Peachtree Street, Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Our Docket: 05213-0880 (43170-249874)

RECEIVED

AUG 15 2002

TECH CENTER 1600/2900

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number



Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	10/042,347
Filing Date	01/11/2002
First Named Inventor	O'Reilly et al.
Group Art Unit	1642
Examiner Name	Sheela Jitendra Huff
Attorney Docket Number	05213-0880 (43170-249874)

Sheet 1 of 6

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number ⁴	Kind Code ³ (if known)			
	1	60/80728		MIXSON, James A.	06/27/2000	

RECEIVED

AUG 15 2002

TECH CENTER 1600/2900

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/042,347
Filing Date	01/11/2002
First Named Inventor	O'Reilly et al.
Group Art Unit	1642
Examiner Name	Sheela Jitendra Huff
Attorney Docket Number	05213-0880 (43170-249874)

Sheet 2 of 6


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**RECEIVED****AUG 15 2002****TECH CENTER 1600/2900**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	2	Author: Title: Chapter 12: Vectors for Gene Therapy Publ: <u>Current Protocols in Human Genetics</u> Vol/Iss: Pages: Date: 1997
	3	Author: BOUSSIF, O. et al. Title: A versatile vector for gene and oligonucleotide transfer into cells in culture and <i>in vivo</i> : Polyethylenimine Publ: <u>Proc. Natl. Acad. Sci. USA</u> Vol/Iss: 92 Pages: 7297-7301 Date: 08/1995
	4	Author: CALOS, MICHELE P. Title: The potential of extrachromosomal replicating vectors for gene therapy Publ: <u>TIG</u> Vol/Iss: 12 (11) Pages: 463-466 Date: 11/1996
	5	Author: CHEN, P. et al. Title: Genetic Mechanisms of Tumor Suppression by the Human p53 Gene Publ: <u>Science</u> Vol/Iss: 250 Pages: 1576-1579 Date: 12/1990
	6	Author: CHENG, PI-WAN Title: Receptor Ligand-Facilitated Gene Transfer: Enhancement of Liposome-Mediated Gene Transfer and Expression by Transferrin Publ: <u>Human Gene Therapy</u> Vol/Iss: 7 Pages: 275-282 Date: 02/10/199
	7	Author: DARDIK, R. et al. Title: The structure of endothelial cell thrombospondin - Characterization of the heparin-binding domains Publ: <u>Eur J Biochem</u> Vol/Iss: 168 (2) Pages: 347-355 Date: 10/15/198
	8	Author: DEBS, R.J. et al. Title: Regulation of Gene Expression <i>in Vivo</i> by Liposome-mediated Delivery of a Purified Transcription Factor Publ: <u>The Journal of Biological Chemistry</u> Vol/Iss: 265 (18) Pages: 10189-10192 Date: 06/25/199

Examiner
SignatureDate
Considered

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for Form 1449/APP

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	10/042,347
Filing Date	01/11/2002
First Named Inventor	O'Reilly et al.
Group Art Unit	1642
Examiner Name	Sheela Jitendra Huff
Attorney Docket Number	05213-0880 (43,781,987)

Sheet 3 of 6

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

AUG 15 2002


TECH CENTER 1600/2900

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number, publisher, city and/or country where published
	9	Author: DIXIT, V.M. et al. Title: A monoclonal antibody against human thrombospondin inhibits platelet aggregation Publ: <u>Proc. Natl. Acad. Sci. USA</u> Vol/Iss: 82 Pages: 3472-3476 Date: 05/1985
	10	Author: FAN et al. Title: Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy Publ: <u>Trends in Pharmacological Sciences</u> Vol/Iss: 16 (2) Pages: 57-66 Date: 02/95
	11	Author: FIDLER et al. Title: The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis Publ: <u>Cell</u> Vol/Iss: 79(2) Pages: 185-188 Date: 10/21/94
	12	Author: FUJIWARA, T. et al. Title: Induction of Chemosensitivity in Human Lung Cancer Cells <i>in Vivo</i> by Adenovirus-mediated Transfer of the Wild-Type p53 Gene Publ: <u>Cancer Research</u> Vol/Iss: 54 Pages: 2287-2291 Date: 05/01/199
	13	Author: GOLDMAN, C.K. et al. Title: In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer Publ: <u>Nature Biotechnology</u> Vol/Iss: 15 Pages: 462-466 Date: 05/1997
	14	Author: HAWKINS, MICHAEL J. M.D. Title: Clinical trials of antiangiogenic agents Publ: <u>Current Opinion in Oncology</u> Vol/Iss: 7 Pages: 90-93 Date: 1995
	15	Author: KING, RALPH P. Jr. Title: Novel Cancer Approach From Noted Scientist Hits Stumbling Block Publ: <u>Wall Street Journal</u> Vol/Iss: Pages: A1, A8 Date: 11/12/199

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ²For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	10/042,347
Filing Date	01/11/2002
First Named Inventor	O'Reilly et al.
Group Art Unit	1642
Examiner Name	Sheela Jitendra Huff

Sheet 4 of 6

Attorney Docket Number 05213-0880 (1170-249-73)

RECEIVED

AUG 15 2002

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

TECH CENTER 1600/2900

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	16	Author: KOSFELD, M.D. et al.	Title: Identification of a New Cell Adhesion Motif in Two Homologous Peptides from the COOH-terminal Cell Binding Domain on Human Thrombospondin		
		Publ: The Journal of Biological Chemistry	Vol/Iss: 268 (12)	Pages: 8808-8814	Date: 1993
	17	Author: LESOON-WOOD, L.A. et al.	Title: Systemic Gene Therapy with p53 Reduces Growth and Metastases of a Malignant Human Breast Tumor in Nude Mice		
		Publ: Human Gene Therapy	Vol/Iss: 6	Pages: 395-405	Date: 04/1995
	18	Author: MAIONE, T.E. et al.	Title: Inhibition of Tumor Growth in Mice by an Analogue of Platelet Factor 4 That Lacks Affinity for Heparin and Retains Potent Angiostatic Activity		
		Publ: Cancer Research	Vol/Iss: 51	Pages: 2077-2083	Date: 04/15/199
	19	Author: MARSHALL, ELIOT	Title: Gene Therapy's Growing Pains		
		Publ: Science	Vol/Iss: 269	Pages: 1050-1055	Date: 08/25/199
	20	Author: O'REILLY et al.	Title: Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth		
		Publ: Cell	Vol/Iss: 88	Pages: 277-285	Date: 01/24/97
	21	Author: PARK et al.	Title: Development of liposome- and anti-HER2 immunoliposomeplasmid complexes for efficient and selective gene therapy		
		Publ: Proceedings of the American Association for Cancer Research	Vol/Iss: 38	Pages: 342	Date: 03/1997
	22	Author: PASQUALINI, R. et al.	Title: α_v Integrins as receptors for tumor targeting by circulating ligands		
		Publ: Nature Biotechnology	Vol/Iss: 15	Pages: 542-546	Date: 06/1997

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ²For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No	10/042,347
Filing Date	01/11/2002
First Named Inventor	O'Reilly et al.
Group Art Unit	1642
Examiner Name	Sheela Jitendra Huff
Attorney Docket Number	05213-0880 (43170-249874)

Sheet 5 of 6

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

RECEIVED

AUG 15 2002


TECH CENTER 1600/2900

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	23	Author: PASQUALINI, R. et al. Title: Organ targeting <i>in vivo</i> using phage display peptide libraries Publ: <u>Nature</u> Vol/Iss: 380 Pages: 364-166 Date: 03/28/199
	24	Author: SAIKI et al. Title: Inhibition of Tumor Angiogenesis by a Synthetic Cell-adhesive Polypeptide Containing the Arg-Gly-Asp (RGD) Sequence of Fibronectin, Poly(RGD) Publ: <u>Jpn. J. Cancer Research</u> Vol/Iss: 81 Pages: 668-675 Date: 1990
	25	Author: SHEIKH et al. Title: Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines Publ: <u>Oncogene</u> Vol/Iss: 11 Pages: 1899-1905 Date: 1995
	26	Author: TANAKA, T. et al. Title: Viral vector-mediated transductions of a modified platelet factor 3 cDNA inhibits angiogenesis and tumor growth Publ: <u>Nature Medicine</u> Vol/Iss: 3 Pages: 437-442 Date: 04/1997
	27	Author: WEINSTAT-SASLOW, D.L. et al. Title: Transfection of Thrombospondin 1 Complementary DNA into a Human Breast Carcinoma Cell Line Reduces Primary Tumor Growth, Metastatic Potential, and Angiogenesis Publ: <u>Cancer Research</u> Vol/Iss: 54 Pages: 6504-6511 Date: 1994
	28	Author: XU, M. et al. Title: In Vivo Gene Therapy with a Cationic Polymer Markedly Enhances the Antitumor Activity of Antiangiogenic Genes Publ: <u>Molecular Genetics and Metabolism</u> Vol/Iss: 64 Pages: 001-005 Date: 1998
	29	Author: XU, M. et al. Title: Gene Therapy with P53 and a Fragment of Thrombospondin 1 Inhibits Human Breast Cancer <i>in Vivo</i> Publ: <u>Molecular Genetics and Metabolism</u> Vol/Iss: 63 Pages: 103-109 Date: 1998

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ²For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	10/042,347
Filing Date	01/11/2002
First Named Inventor	O'Reilly et al.
Group Art. Unit	1642
Examiner Name	Sheela Jitendra Huff
Attorney Docket Number	05213-0880 (43170-249874)

Sheet 6 of 6

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	30	Author: XU, M. et al. Title: Parenteral Gene Therapy with p53 Inhibits Human Breat Tumors <i>In Vivo</i> Through a Bystander Mechanism Without Evidence of Toxicity Publ: Human Gene Therapy Vol/Iss: 8 Pages: 177-185 Date: 01/20/199	
	31	Author: ZABRENETZKY, V. et al. Title: EXPRESSION OF THE EXTRACELLULAR MATRIX MOLECULE THROMBOSPONDIN INVERSELY CORRELATES WITH MALIGNANT PROGRESSION IN MELANOMA, LUNG AND BREAST CARCINOMA CELL Publ: Int. J. Cancer Vol/Iss: 59 Pages: 191-195 Date: 1994	
	32	Author: ZHU, N. et al. Title: Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice Publ: Science Vol/Iss: 261 Pages: 209-211 Date: 07/09/199	

RECEIVED

AUG 15 2002

TECH CENTER 1600/2900

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.